


# Cascata coagulativa

## Regolazione Naturale

Tissue pathway factor inhibitor (TFPI)

Disolfuro Isomerasi (PDI)



# SISTEMI ANTICOAGULANTI NATURALI

**Effettore**

**Target**

**Inibitore del fattore  
tissutale (TFPI)**

**FVIIa-FT**

**Sistema Antitrombina-  
eparina**

**Enzimi (XIIa, XIa,  
IXa, Xa, IIa, VIIa)**


**Sistema della Proteina C**

**Cofattori attivati  
(VIIIa, Va)**


# TFPI

# ANTITROMBINA


# PROTEINA C




# Rapporti distrettuali tra superficie endoteliale e sangue circolante



# TFPI, inibitore del Xa




# TFPI-Xa, inibitore di VIIa-FT



**VIIa-FT**

**TIFPI-Xa**



# DNA

**A DNA template was synthesized with the sequence 5'-GGAGGGAAAAGTTATCAGGC-N40-GATTAGTTTTGGAGTACTCGCTCC-3'**

**“N40” =40-nucleotide sequence in which there is an equal probability of incorporating a dA, dC, dG, or dT residue at each position and  
“d” = 2'-H residue**

**The DNA template was amplified by polymerase chain reaction (PCR) with forward primer 5'-GACTGTAATACGACTCACTATAGGAGGGAAAAGTTATC-AGGC-3' and reverse primer 5'-GGAGCGAGTACTCCAAAATAATC-3'**

# RNA -selection

- Transcribed to generate a starting pool of approximately  $10^{14}$  different sequences comprised of dC, mA, mG, and mU residues,

“m” = 2'-OCH<sub>3</sub> residue

11 rounds of selection were carried out by first incubating the pool of molecules with recombinant full-length TFPI

- The round 11 pool was cloned and sequenced.
- Individual clones were generated by chemical synthesis
- Clones were tested for

binding to recombinant TFPI with a nitrocellulose dot blot binding assay and for inhibition of TFPI in the calibrated automated thrombogram (CAT) assay


- the parent clone (5'-mGmGmAmGmGmGmAmAmAmAmGmUmUmA-mUdCmAmGmGdCdCmUmGmAmAmUmUmUmGmGmAmAmUmAmUmAdCmUmUmGmGdCmUdCmGmUmUmAmGmGmUmGdCmGmUmAmUmAmUmAmGmAmUmUmAmGmUmUmUmUmGmGmAmGmUmAdCmUdCmGdCmUdCdC-3') was determined to bind to TFPI with nanomolar affinity and inhibit its activity in plasma at nanomolar concentrations.



# Synthesis modification


- The core aptamer motif, **ARC17480**, was identified by design of molecules that contained a portion of the parent clone sequence and evaluation in the same assays.
- The core aptamer was synthesized with a hexylamine linker  $-\text{CH}_3(\text{CH}_2)_5\text{NH}_2$  - at the 5'-end
- which was conjugated postsynthetically to a branched 40 kDa PEG moiety -  $(\text{HO}-\text{CH}_2-(\text{CH}_2-\text{O}-\text{CH}_2-)_n-\text{CH}_2-\text{OH})$  - to give rise to **ARC19499**.

## ARC17480 binding to TFPI and other proteins.




Waters E K et al. Blood 2011;117:5514-5522

## ARC17480 binding to TFPI and other proteins.



Waters E K et al. Blood 2011;117:5514-5522


## ARC17480 binding to TFPI and other proteins.



Waters E K et al. Blood 2011;117:5514-5522

ARC17480 and ARC19499 binding to TFPI and other proteins.


10nM TFPI + radiolabeled ARC17480



Waters E K et al. Blood 2011;117:5514-5522


## Activity of ARC19499 in TFPI-dependent assays using purified proteins.

A



Waters E K et al. Blood 2011;117:5514-5522


ARC19499 inhibition of TFPI in human plasma.



Waters E K et al. Blood 2011;117:5514-5522

ARC19499 inhibition of TFPI in human plasma.

TFPI-depleted plasma




Waters E K et al. Blood 2011;117:5514-5522



ARC19499 effect on thrombin generation in human plasma.

Activity in hemophilia A plasma



Normal plasma (solid lines)

Hemophilia (dashed lines)


+ ARC19499 (◆)

+ negative control oligonucleotide (■).

Waters E K et al. Blood 2011;117:5514-5522

ARC19499 effect on thrombin generation in human plasma.

Activity in hemophilia B plasma



Hemophilia B+ aptamer  
normal plasma

Hemophilia B

Normal plasma (solid lines)

Hemophilia (dashed lines)


+ ARC19499 (◆)

+ negative control oligonucleotide (■).

Waters E K et al. Blood 2011;117:5514-5522

ARC19499 effect on thrombin generation in human plasma.

Activity in plasma with antibody inhibitor



Normal plasma (solid lines)

Hemophilia (dashed lines)

+ ARC19499 (◆)

+ negative control oligonucleotide (■).

Waters E K et al. Blood 2011;117:5514-5522